and follow-up Ultomiris (ravulizumab). Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.4 bn, setting up one of the largest private equity buyouts in Japan's health sector.

and longer-acting follow-up Ultomiris (ravulizumab), which are given intravenously every two and eight weeks, respectively. Those two drugs made around $3.8 billion and $2 billion respectively ...